What is a tumor board and should my CLL case be reviewed by one

CLLMay 17, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Tumor Boards and CLL Care

What Is a Tumor Board?

A tumor board (also called a multidisciplinary tumor conference or case conference) is a meeting where a team of cancer specialists from different areas of medicine review individual patient cases together. Think of it as a "second opinion by committee."

Who typically participates:

  • Medical oncologists (cancer doctors)
  • Hematologists (blood specialists)
  • Pathologists (doctors who examine tissue samples)
  • Radiologists (imaging specialists)
  • Surgeons (when relevant)
  • Nurses and other specialists
  • Sometimes genetic counselors

What they do: The team reviews your [ID removed] test results, imaging scans, and pathology reports. They discuss your specific situation and recommend treatment approaches based on current medical evidence and guidelines.


Should Your CLL Case Be Reviewed by a Tumor Board?

The short answer: It's worth discussing with your oncologist.

For CLL specifically, tumor board review can be particularly valuable in certain situations:

When Tumor Board Review Is Most Helpful:

Complex or unusual presentations - If your CLL has features that make treatment decisions less straightforward

Richter transformation - According to NCCN Guidelines, if your CLL transforms into diffuse large B-cell lymphoma (DLBCL), this is a serious complication that benefits from expert review. The NCCN Guidelines note that "enrollment in a clinical trial is the preferred initial treatment option for Richter transformation," and a tumor board can help identify appropriate trials and treatment strategies.

Treatment-resistant disease - If your CLL isn't responding well to initial therapy

Multiple treatment options - When several reasonable approaches exist and you want expert input on which might be best for YOUR situation

Rare genetic features - If your CLL has specific mutations (like TP53 mutations or del(17p)) that affect treatment planning

Considering clinical trials - A tumor board can help identify appropriate research studies


Questions to Ask Your Oncologist

  1. "Do you think my case would benefit from tumor board review?"

  2. "Are there specific aspects of my case you'd like discussed with other specialists?"

  3. "How would tumor board recommendations affect my current treatment plan?"

  4. "Can you help me access tumor board review if I want it?"

  5. "Are there clinical trials that a tumor board might identify for my situation?"


How to Access Tumor Board Review

  • Ask your oncologist directly - They can request review at their institution
  • Academic cancer centers - Usually have active tumor boards and may be more accessible
  • NCCN Member Institutions - The NCCN Guidelines are developed by experts at major cancer centers that typically have robust tumor board programs
  • Second opinion centers - Some specialized CLL centers offer comprehensive case reviews

Important Context for CLL

According to the NCCN Guidelines for Chronic Lymphocytic Leukemia, treatment decisions increasingly depend on:

  • Your specific genetic and molecular features
  • Whether your disease is early-stage or advanced
  • Your age and overall health
  • Your preferences regarding treatment intensity

These factors make CLL increasingly personalized, which is exactly what tumor boards are designed to address—bringing together experts to tailor recommendations to YOUR specific case rather than applying a one-size-fits-all approach.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: